{"transactions":[{"id":671118,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T21:01:54.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9730,"price":49.13,"value":478034.9,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":35.87,"expiration_date":"2036-06-18","underlying":"Common Stock","underlying_shares":9730},"source":{"system":"sec-edgar","filing":"0001628280-26-059905","document":"wk-form4_1788296511.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059905/wk-form4_1788296511.xml","form_type":"4"}},{"id":671117,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T21:01:54.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10350,"price":52.67,"value":545134.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":32.33,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":10350},"source":{"system":"sec-edgar","filing":"0001628280-26-059905","document":"wk-form4_1788296511.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059905/wk-form4_1788296511.xml","form_type":"4"}},{"id":671116,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T21:01:54.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12500,"price":40.29,"value":503625.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":44.71,"expiration_date":"2034-06-07","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001628280-26-059905","document":"wk-form4_1788296511.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059905/wk-form4_1788296511.xml","form_type":"4"}},{"id":671115,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T21:01:54.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17500,"price":64.68,"value":1131900.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":20.32,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001628280-26-059905","document":"wk-form4_1788296511.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059905/wk-form4_1788296511.xml","form_type":"4"}},{"id":671114,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T21:01:54.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17500,"price":64.77,"value":1133475.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":20.23,"expiration_date":"2031-06-22","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001628280-26-059905","document":"wk-form4_1788296511.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059905/wk-form4_1788296511.xml","form_type":"4"}},{"id":671113,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T21:01:54.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12500,"price":61.77,"value":772125.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":23.23,"expiration_date":"2030-06-19","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001628280-26-059905","document":"wk-form4_1788296511.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059905/wk-form4_1788296511.xml","form_type":"4"}},{"id":671112,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T21:01:54.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25000,"price":60.85,"value":1521250.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":24.15,"expiration_date":"2029-07-15","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001628280-26-059905","document":"wk-form4_1788296511.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059905/wk-form4_1788296511.xml","form_type":"4"}},{"id":671111,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-01T21:01:54.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5925,"price":85,"value":503625.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a \"Company RSU\"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective Time, each Company RSU that was then outstanding but not vested became immediately vested in full. At the Effective Time, each outstanding Company RSU was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration, less any applicable tax withholding."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001628280-26-059905","document":"wk-form4_1788296511.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059905/wk-form4_1788296511.xml","form_type":"4"}},{"id":671110,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-01T21:01:54.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6400,"price":85,"value":544000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the \"Merger Agreement\"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the \"Company\"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (\"Parent\"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of September 1, 2026 (the \"Effective Time\"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the \"Company Common Stock\"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the \"Merger Consideration\")."}],"balance_after":5925,"source":{"system":"sec-edgar","filing":"0001628280-26-059905","document":"wk-form4_1788296511.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059905/wk-form4_1788296511.xml","form_type":"4"}},{"id":730457,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-22T21:00:02.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":9730,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":9730,"derivative":{"exercise_price":35.87,"expiration_date":"2036-06-18","underlying":"Common Stock","underlying_shares":9730},"source":{"system":"sec-edgar","filing":"0001628280-26-044708","document":"wk-form4_1782161999.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026044708/wk-form4_1782161999.xml","form_type":"4"}},{"id":730456,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-22T21:00:02.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":5925,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the\nfirst anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through\nsuch vesting date."}],"balance_after":12325,"source":{"system":"sec-edgar","filing":"0001628280-26-044708","document":"wk-form4_1782161999.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026044708/wk-form4_1782161999.xml","form_type":"4"}},{"id":732080,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-18T21:23:45.000Z","date":"2026-06-17","kind":"sale","planned":true,"acquired":false,"shares":608,"price":36.22,"value":22021.76,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sale price of $36.22 per share. The range of sale prices on\nthe transaction date was $36.19 to $36.29. Detailed information on the exact number of shares can be obtained from the Issuer upon request."}],"balance_after":6400,"source":{"system":"sec-edgar","filing":"0001628280-26-044419","document":"wk-form4_1781817823.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026044419/wk-form4_1781817823.xml","form_type":"4"}},{"id":732079,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-18T21:23:45.000Z","date":"2026-06-17","kind":"sale","planned":true,"acquired":false,"shares":6292,"price":35.62,"value":224121.04,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sale price of $35.62 per share. The range of sale prices on\nthe transaction date was $35.19 to $36.06. Detailed information on the exact number of shares can be obtained from the Issuer upon request."}],"balance_after":7008,"source":{"system":"sec-edgar","filing":"0001628280-26-044419","document":"wk-form4_1781817823.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026044419/wk-form4_1781817823.xml","form_type":"4"}},{"id":846989,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-12T21:20:05.000Z","date":"2026-03-10","kind":"exercise","planned":true,"acquired":false,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 24, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Currently exercisable."}],"balance_after":0,"derivative":{"exercise_price":33.63,"expiration_date":"2028-12-13","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001742616-26-000006","document":"form4-03122026_050301.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000174261626000006/form4-03122026_050301.xml","form_type":"4"}},{"id":846988,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-12T21:20:05.000Z","date":"2026-03-10","kind":"exercise","planned":true,"acquired":false,"shares":1167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 24, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Currently exercisable."}],"balance_after":0,"derivative":{"exercise_price":33.63,"expiration_date":"2028-12-13","underlying":"Common Stock","underlying_shares":1167},"source":{"system":"sec-edgar","filing":"0001742616-26-000006","document":"form4-03122026_050301.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000174261626000006/form4-03122026_050301.xml","form_type":"4"}},{"id":846987,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-12T21:20:05.000Z","date":"2026-03-10","kind":"sale","planned":true,"acquired":false,"shares":14000,"price":70,"value":980000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 24, 2025."}],"balance_after":8000,"source":{"system":"sec-edgar","filing":"0001742616-26-000006","document":"form4-03122026_050301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000174261626000006/form4-03122026_050301.xml","form_type":"4"}},{"id":846986,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-12T21:20:05.000Z","date":"2026-03-10","kind":"exercise","planned":true,"acquired":true,"shares":14000,"price":33.63,"value":470820.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 24, 2025."}],"balance_after":22000,"source":{"system":"sec-edgar","filing":"0001742616-26-000006","document":"form4-03122026_050301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000174261626000006/form4-03122026_050301.xml","form_type":"4"}},{"id":846985,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-12T21:20:05.000Z","date":"2026-03-10","kind":"sale","planned":true,"acquired":false,"shares":1167,"price":70,"value":81690.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 24, 2025."}],"balance_after":8000,"source":{"system":"sec-edgar","filing":"0001742616-26-000006","document":"form4-03122026_050301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000174261626000006/form4-03122026_050301.xml","form_type":"4"}},{"id":846984,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-12T21:20:05.000Z","date":"2026-03-10","kind":"exercise","planned":true,"acquired":true,"shares":1167,"price":33.63,"value":39246.21,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 24, 2025."}],"balance_after":9167,"source":{"system":"sec-edgar","filing":"0001742616-26-000006","document":"form4-03122026_050301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000174261626000006/form4-03122026_050301.xml","form_type":"4"}},{"id":854433,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-09T21:20:10.000Z","date":"2026-03-05","kind":"sale","planned":true,"acquired":false,"shares":6333,"price":63.38,"value":401385.54,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 24, 2025."}],"balance_after":8000,"source":{"system":"sec-edgar","filing":"0001742616-26-000004","document":"form4-03092026_050305.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000174261626000004/form4-03092026_050305.xml","form_type":"4"}},{"id":861576,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-04T22:44:48.000Z","date":"2026-03-03","kind":"sale","planned":true,"acquired":false,"shares":3000,"price":39.67,"value":119010.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a sale price of $39.67 per share."}],"balance_after":13300,"source":{"system":"sec-edgar","filing":"0001628280-26-014775","document":"wk-form4_1772664285.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026014775/wk-form4_1772664285.xml","form_type":"4"}},{"id":947919,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-06T22:20:16.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":3475,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on January 2, 2026 and vests over one year in twelve equal monthly installments, commencing on February 2, 2026."}],"balance_after":3475,"derivative":{"exercise_price":76.74,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":3475},"source":{"system":"sec-edgar","filing":"0001742616-26-000002","document":"form4-01062026_050110.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000174261626000002/form4-01062026_050110.xml","form_type":"4"}},{"id":947918,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-06T22:20:16.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock units granted on January 2, 2026 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 2, 2026 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 2, 2027."}],"balance_after":12000,"source":{"system":"sec-edgar","filing":"0001742616-26-000002","document":"form4-01062026_050110.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000174261626000002/form4-01062026_050110.xml","form_type":"4"}},{"id":991681,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-21T22:20:05.000Z","date":"2025-11-20","kind":"gift","planned":false,"acquired":false,"shares":867,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the Reporting Person's bona fide gift of shares of the issuer's common stock to a charitable organization."}],"balance_after":8000,"source":{"system":"sec-edgar","filing":"0001742616-25-000006","document":"form4-11212025_051101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000174261625000006/form4-11212025_051101.xml","form_type":"4"}},{"id":1111624,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-13T20:30:20.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":10350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":10350,"derivative":{"exercise_price":32.33,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":10350},"source":{"system":"sec-edgar","filing":"0000950170-25-086267","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017025086267/ownership.xml","form_type":"4"}},{"id":1111623,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T20:30:20.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":6900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":16300,"source":{"system":"sec-edgar","filing":"0000950170-25-086267","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017025086267/ownership.xml","form_type":"4"}},{"id":1204660,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-17T21:20:05.000Z","date":"2025-03-13","kind":"sale","planned":false,"acquired":false,"shares":5000,"price":54,"value":270000.0,"ownership":{"direct":true},"balance_after":8867,"source":{"system":"sec-edgar","filing":"0001415889-25-008235","document":"form4-03172025_050301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000141588925008235/form4-03172025_050301.xml","form_type":"4"}},{"id":1308709,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-07T22:20:26.000Z","date":"2025-01-03","kind":"grant","planned":false,"acquired":true,"shares":8800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on January 3, 2025 and vests over one year in twelve equal monthly installments, commencing on February 3, 2025."}],"balance_after":8800,"derivative":{"exercise_price":46.54,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":8800},"source":{"system":"sec-edgar","filing":"0001415889-25-001024","document":"form4-01072025_050120.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000141588925001024/form4-01072025_050120.xml","form_type":"4"}},{"id":1308708,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-07T22:20:26.000Z","date":"2025-01-03","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock units granted on January 3, 2025 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 17, 2025 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 3, 2026."}],"balance_after":13867,"source":{"system":"sec-edgar","filing":"0001415889-25-001024","document":"form4-01072025_050120.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000141588925001024/form4-01072025_050120.xml","form_type":"4"}},{"id":1326233,"issuer":{"id":16279,"kind":"organization","name":"Catalent, Inc.","symbol":"CTLT"},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-18T13:08:55.000Z","date":"2024-12-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12635,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 18, 2024, Creek Parent, Inc., a Delaware corporation (\"Parent\"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Creek Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (\"Merger Sub\"), dated as of February 5, 2024 (the \"Merger Agreement\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the \"Merger\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"Includes restricted stock units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the effective time of the Merger (the \"Effective Time\"), each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $63.50 in cash, without interest (the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Effective Time, each RSU, whether or not vested, outstanding immediately prior to the Effective Time vested (if unvested) and was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the total number of shares of Issuer common stock subject to the RSU multiplied by (ii) the Merger Consideration, except for certain RSUs granted following the date of the Merger Agreement which were converted at the Effective Time into restricted cash awards equal to the product of (a) the Merger Consideration multiplied by (b) the number of shares of Issuer common stock subject to such award and otherwise remain subject to their terms, including vesting and acceleration terms."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-137726","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1596783/000095017024137726/ownership.xml","form_type":"4"}},{"id":1377997,"issuer":{"id":16279,"kind":"organization","name":"Catalent, Inc.","symbol":"CTLT"},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-01T17:17:29.000Z","date":"2024-10-30","kind":"grant","planned":false,"acquired":true,"shares":4663,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The equity acquired by the reporting person is the annual grant of restricted stock units provided by the Issuer to the reporting person pursuant to the Issuer's non-employee director compensation program. Each restricted stock unit represents the right to receive one share of the Issuer's common stock as of the date of vesting, which will occur on the earlier of (i) a \"change in control\" (as defined in the Catalent, Inc. 2018 Omnibus Incentive Plan) and (ii) one year from the date of award, subject to continued service."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes restricted stock units."}],"balance_after":12635,"source":{"system":"sec-edgar","filing":"0001596783-24-000109","document":"wk-form4_1730495843.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1596783/000159678324000109/wk-form4_1730495843.xml","form_type":"4"}},{"id":1483433,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-11T20:20:49.000Z","date":"2024-06-07","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall vest and become exercisable on the earlier of the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":12500,"derivative":{"exercise_price":44.71,"expiration_date":"2034-06-07","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0000950170-24-071928","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017024071928/ownership.xml","form_type":"4"}},{"id":1483432,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-11T20:20:49.000Z","date":"2024-06-07","kind":"grant","planned":false,"acquired":true,"shares":3400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":9400,"source":{"system":"sec-edgar","filing":"0000950170-24-071928","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017024071928/ownership.xml","form_type":"4"}},{"id":1553511,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-04-02T20:35:30.000Z","date":"2024-03-28","kind":"exercise","planned":false,"acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":0,"derivative":{"exercise_price":18.29,"expiration_date":"2032-06-17","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001209191-24-005184","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919124005184/doc4.xml","form_type":"4"}},{"id":1553510,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-02T20:35:30.000Z","date":"2024-03-28","kind":"sale","planned":false,"acquired":false,"shares":17500,"price":46.38,"value":811650.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $46.38 per share. The range of sales prices on the transaction date was $46.06 to $46.66 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":6000,"source":{"system":"sec-edgar","filing":"0001209191-24-005184","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919124005184/doc4.xml","form_type":"4"}},{"id":1553509,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-02T20:35:30.000Z","date":"2024-03-28","kind":"exercise","planned":false,"acquired":true,"shares":17500,"price":18.29,"value":320075.0,"ownership":{"direct":true},"balance_after":23500,"source":{"system":"sec-edgar","filing":"0001209191-24-005184","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919124005184/doc4.xml","form_type":"4"}},{"id":1639149,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-16T21:16:57.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on February 15, 2024 and vests over one year in twelve equal monthly installments, commencing on March 15, 2024."}],"balance_after":10000,"derivative":{"exercise_price":25.69,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-24-004116","document":"form4-02162024_090223.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000141588924004116/form4-02162024_090223.xml","form_type":"4"}},{"id":1639148,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-16T21:16:57.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock units granted on February 15, 2024 that vest over one year, with one-third (1/3) of the shares underlying the RSUs vesting on June 18, 2024 and the remaining two-thirds (2/3) of the original shares underlying the RSUs vesting on February 15, 2025."}],"balance_after":9867,"source":{"system":"sec-edgar","filing":"0001415889-24-004116","document":"form4-02162024_090223.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000141588924004116/form4-02162024_090223.xml","form_type":"4"}},{"id":1753019,"issuer":{"id":16279,"kind":"organization","name":"Catalent, Inc.","symbol":"CTLT"},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-10-31T16:24:23.000Z","date":"2023-10-27","kind":"grant","planned":false,"acquired":true,"shares":6993,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The equity acquired by the reporting person is the annual grant of restricted stock units provided by the Issuer to the reporting person pursuant to the Issuer's non-employee director compensation program. Each restricted stock unit represents the right to receive one share of the Issuer's common stock as of the date of vesting, which will occur one year from the date of award, subject to continued service."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes restricted stock units."}],"balance_after":7972,"source":{"system":"sec-edgar","filing":"0001596783-23-000139","document":"wk-form4_1698783849.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1596783/000159678323000139/wk-form4_1698783849.xml","form_type":"4"}},{"id":1792755,"issuer":{"id":16279,"kind":"organization","name":"Catalent, Inc.","symbol":"CTLT"},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-30T19:12:57.000Z","date":"2023-08-28","kind":"grant","planned":false,"acquired":true,"shares":979,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The equity acquired by the reporting person is the regular, annual grant of restricted stock units (pro-rated to reflect a partial year of service) provided by the Issuer to the reporting person pursuant to the Issuer's non-management director compensation package. Each restricted stock unit represents the right to receive one share of the Issuer's common stock as of the date of vesting, which will occur one year from the date of award."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents restricted stock units."}],"balance_after":979,"source":{"system":"sec-edgar","filing":"0001596783-23-000123","document":"wf-form4_169343716360051.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1596783/000159678323000123/wf-form4_169343716360051.xml","form_type":"4"}},{"id":1847817,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-21T21:00:33.000Z","date":"2023-06-16","kind":"grant","planned":false,"acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":17500,"derivative":{"exercise_price":20.32,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001209191-23-038822","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919123038822/doc4.xml","form_type":"4"}},{"id":1847816,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-21T21:00:33.000Z","date":"2023-06-16","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":6000,"source":{"system":"sec-edgar","filing":"0001209191-23-038822","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919123038822/doc4.xml","form_type":"4"}},{"id":1978964,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-03-02T17:01:28.000Z","date":"2023-03-02","kind":"disposition_to_issuer","acquired":false,"shares":11000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the \"Merger Agreement\"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation (\"Parent\"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee (\"Guarantor\"), and the Issuer, pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.01 par value per share (each, a \"Share\")"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) and thereafter merged with and into the Issuer (the \"Merger\"), effective as of March 2, 2023 (the \"Effective Time\"). At the Effective Time, (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from Footnote 2) (B) one non-tradeable contractual contingent value right (\"CVR\") for each Share subject to such In the Money Option immediately prior to the Effective Time, which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest, upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement on or prior to December 31, 2027; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration and had no further force or effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the \"Merger Agreement\"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation (\"Parent\"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee (\"Guarantor\"), and the Issuer, pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.01 par value per share (each, a \"Share\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) and thereafter merged with and into the Issuer (the \"Merger\"), effective as of March 2, 2023 (the \"Effective Time\"). At the Effective Time, (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued from Footnote 2) (B) one non-tradeable contractual contingent value right (\"CVR\") for each Share subject to such In the Money Option immediately prior to the Effective Time, which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest, upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement on or prior to December 31, 2027; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration and had no further force or effect."}],"balance_after":0,"derivative":{"exercise_price":30.68,"expiration_date":"2028-06-07","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001209191-23-014801","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919123014801/doc4.xml","form_type":"4"}},{"id":1978963,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-03-02T17:01:28.000Z","date":"2023-03-02","kind":"disposition_to_issuer","acquired":false,"shares":5500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the \"Merger Agreement\"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation (\"Parent\"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee (\"Guarantor\"), and the Issuer, pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.01 par value per share (each, a \"Share\")"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) and thereafter merged with and into the Issuer (the \"Merger\"), effective as of March 2, 2023 (the \"Effective Time\"). At the Effective Time, (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from Footnote 2) (B) one non-tradeable contractual contingent value right (\"CVR\") for each Share subject to such In the Money Option immediately prior to the Effective Time, which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest, upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement on or prior to December 31, 2027; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration and had no further force or effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the \"Merger Agreement\"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation (\"Parent\"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee (\"Guarantor\"), and the Issuer, pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.01 par value per share (each, a \"Share\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) and thereafter merged with and into the Issuer (the \"Merger\"), effective as of March 2, 2023 (the \"Effective Time\"). At the Effective Time, (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued from Footnote 2) (B) one non-tradeable contractual contingent value right (\"CVR\") for each Share subject to such In the Money Option immediately prior to the Effective Time, which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest, upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement on or prior to December 31, 2027; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration and had no further force or effect."}],"balance_after":0,"derivative":{"exercise_price":32.53,"expiration_date":"2028-06-14","underlying":"Common Stock","underlying_shares":5500},"source":{"system":"sec-edgar","filing":"0001209191-23-014801","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919123014801/doc4.xml","form_type":"4"}},{"id":1978962,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-03-02T17:01:28.000Z","date":"2023-03-02","kind":"disposition_to_issuer","acquired":false,"shares":5500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the \"Merger Agreement\"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation (\"Parent\"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee (\"Guarantor\"), and the Issuer, pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.01 par value per share (each, a \"Share\")"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) and thereafter merged with and into the Issuer (the \"Merger\"), effective as of March 2, 2023 (the \"Effective Time\"). At the Effective Time, (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from Footnote 2) (B) one non-tradeable contractual contingent value right (\"CVR\") for each Share subject to such In the Money Option immediately prior to the Effective Time, which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest, upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement on or prior to December 31, 2027; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration and had no further force or effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the \"Merger Agreement\"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation (\"Parent\"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee (\"Guarantor\"), and the Issuer, pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.01 par value per share (each, a \"Share\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) and thereafter merged with and into the Issuer (the \"Merger\"), effective as of March 2, 2023 (the \"Effective Time\"). At the Effective Time, (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued from Footnote 2) (B) one non-tradeable contractual contingent value right (\"CVR\") for each Share subject to such In the Money Option immediately prior to the Effective Time, which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest, upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement on or prior to December 31, 2027; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration and had no further force or effect."}],"balance_after":0,"derivative":{"exercise_price":31.22,"expiration_date":"2029-06-20","underlying":"Common Stock","underlying_shares":5500},"source":{"system":"sec-edgar","filing":"0001209191-23-014801","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919123014801/doc4.xml","form_type":"4"}},{"id":1978961,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-03-02T17:01:28.000Z","date":"2023-03-02","kind":"disposition_to_issuer","acquired":false,"shares":8000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the \"Merger Agreement\"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation (\"Parent\"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee (\"Guarantor\"), and the Issuer, pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.01 par value per share (each, a \"Share\")"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) and thereafter merged with and into the Issuer (the \"Merger\"), effective as of March 2, 2023 (the \"Effective Time\"). At the Effective Time, (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from Footnote 2) (B) one non-tradeable contractual contingent value right (\"CVR\") for each Share subject to such In the Money Option immediately prior to the Effective Time, which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest, upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement on or prior to December 31, 2027; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration and had no further force or effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the \"Merger Agreement\"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation (\"Parent\"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee (\"Guarantor\"), and the Issuer, pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.01 par value per share (each, a \"Share\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) and thereafter merged with and into the Issuer (the \"Merger\"), effective as of March 2, 2023 (the \"Effective Time\"). At the Effective Time, (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued from Footnote 2) (B) one non-tradeable contractual contingent value right (\"CVR\") for each Share subject to such In the Money Option immediately prior to the Effective Time, which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest, upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement on or prior to December 31, 2027; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration and had no further force or effect."}],"balance_after":0,"derivative":{"exercise_price":27.89,"expiration_date":"2030-06-18","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001209191-23-014801","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919123014801/doc4.xml","form_type":"4"}},{"id":1978960,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-03-02T17:01:28.000Z","date":"2023-03-02","kind":"disposition_to_issuer","acquired":false,"shares":8000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the \"Merger Agreement\"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation (\"Parent\"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee (\"Guarantor\"), and the Issuer, pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.01 par value per share (each, a \"Share\")"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) and thereafter merged with and into the Issuer (the \"Merger\"), effective as of March 2, 2023 (the \"Effective Time\"). At the Effective Time, (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from Footnote 2) (B) one non-tradeable contractual contingent value right (\"CVR\") for each Share subject to such In the Money Option immediately prior to the Effective Time, which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest, upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement on or prior to December 31, 2027; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration and had no further force or effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the \"Merger Agreement\"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation (\"Parent\"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee (\"Guarantor\"), and the Issuer, pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.01 par value per share (each, a \"Share\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) and thereafter merged with and into the Issuer (the \"Merger\"), effective as of March 2, 2023 (the \"Effective Time\"). At the Effective Time, (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued from Footnote 2) (B) one non-tradeable contractual contingent value right (\"CVR\") for each Share subject to such In the Money Option immediately prior to the Effective Time, which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest, upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement on or prior to December 31, 2027; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration and had no further force or effect."}],"balance_after":0,"derivative":{"exercise_price":36.87,"expiration_date":"2031-06-23","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001209191-23-014801","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919123014801/doc4.xml","form_type":"4"}},{"id":1978959,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-03-02T17:01:28.000Z","date":"2023-03-02","kind":"disposition_to_issuer","acquired":false,"shares":8000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the \"Merger Agreement\"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation (\"Parent\"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee (\"Guarantor\"), and the Issuer, pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.01 par value per share (each, a \"Share\")"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) and thereafter merged with and into the Issuer (the \"Merger\"), effective as of March 2, 2023 (the \"Effective Time\"). At the Effective Time, (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from Footnote 2) (B) one non-tradeable contractual contingent value right (\"CVR\") for each Share subject to such In the Money Option immediately prior to the Effective Time, which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest, upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement on or prior to December 31, 2027; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration and had no further force or effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the \"Merger Agreement\"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation (\"Parent\"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee (\"Guarantor\"), and the Issuer, pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.01 par value per share (each, a \"Share\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) and thereafter merged with and into the Issuer (the \"Merger\"), effective as of March 2, 2023 (the \"Effective Time\"). At the Effective Time, (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued from Footnote 2) (B) one non-tradeable contractual contingent value right (\"CVR\") for each Share subject to such In the Money Option immediately prior to the Effective Time, which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest, upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement on or prior to December 31, 2027; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration and had no further force or effect."}],"balance_after":0,"derivative":{"exercise_price":19.47,"expiration_date":"2032-06-23","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001209191-23-014801","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919123014801/doc4.xml","form_type":"4"}},{"id":2059214,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-09T21:08:13.000Z","date":"2023-01-05","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on January 5, 2023 and vests over one year in twelve equal monthly installments, commencing on February 5, 2023."}],"balance_after":10000,"derivative":{"exercise_price":39.42,"expiration_date":"2033-01-04","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-23-000667","document":"form4-01092023_090156.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000141588923000667/form4-01092023_090156.xml","form_type":"4"}},{"id":2059213,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-09T21:08:13.000Z","date":"2023-01-05","kind":"grant","acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock units granted on January 5, 2023 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 6, 2023 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 5, 2024."}],"balance_after":5867,"source":{"system":"sec-edgar","filing":"0001415889-23-000667","document":"form4-01092023_090156.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000141588923000667/form4-01092023_090156.xml","form_type":"4"}},{"id":2188402,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-11T20:28:41.000Z","date":"2022-08-09","kind":"sale","acquired":false,"shares":2296,"price":51.621,"value":118521.816,"ownership":{"direct":true},"balance_after":1867,"source":{"system":"sec-edgar","filing":"0001415889-22-008493","document":"form4-08112022_010824.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000141588922008493/form4-08112022_010824.xml","form_type":"4"}},{"id":2220028,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-28T16:01:57.000Z","date":"2022-06-24","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest and become exercisable in full on the earlier of (i) June 24, 2023 or (ii) the day prior to the issuer's 2023 annual meeting of stockholders, subject to the director's continued service on the issuer's board of directors on the vesting date."}],"balance_after":8000,"derivative":{"exercise_price":19.47,"expiration_date":"2032-06-23","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001209191-22-039594","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919122039594/doc4.xml","form_type":"4"}},{"id":2225436,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-21T20:46:58.000Z","date":"2022-06-17","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The entire number of shares subject to this option become fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":17500,"derivative":{"exercise_price":18.29,"expiration_date":"2032-06-16","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001209191-22-038440","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919122038440/doc4.xml","form_type":"4"}},{"id":2438146,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right To Buy)","published_at":"2022-01-11T21:11:42.000Z","date":"2022-01-07","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on January 7, 2022 and vests over one year in twelve equal monthly installments, commencing on February 7, 2022."}],"balance_after":12000,"derivative":{"exercise_price":38.1,"expiration_date":"2032-01-06","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001179110-22-000388","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000117911022000388/edgar.xml","form_type":"4"}},{"id":2438145,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-11T21:11:42.000Z","date":"2022-01-07","kind":"grant","acquired":true,"shares":3200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock units granted on January 7, 2022 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 8, 2022 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 7, 2023."}],"balance_after":4163,"source":{"system":"sec-edgar","filing":"0001179110-22-000388","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000117911022000388/edgar.xml","form_type":"4"}},{"id":2600913,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-17T20:04:52.000Z","date":"2021-08-13","kind":"sale","acquired":false,"shares":1650,"price":40.057,"value":66094.05,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $40.05 to $40.06 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":963,"source":{"system":"sec-edgar","filing":"0001179110-21-008233","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000117911021008233/edgar.xml","form_type":"4"}},{"id":2653166,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-28T16:13:20.000Z","date":"2021-06-24","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest and become exercisable in full on the earlier of (i) June 24, 2022 or (ii) the day prior to the issuer's 2022 annual meeting of stockholders, subject to the director's continued service on the issuer's board of directors on the vesting date."}],"balance_after":8000,"derivative":{"exercise_price":36.87,"expiration_date":"2031-06-23","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001209191-21-043478","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919121043478/doc4.xml","form_type":"4"}},{"id":2657097,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-23T21:00:26.000Z","date":"2021-06-22","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The entire number of shares subject to this option become fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":17500,"derivative":{"exercise_price":20.23,"expiration_date":"2031-06-21","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001209191-21-042767","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919121042767/doc4.xml","form_type":"4"}},{"id":2912630,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right To Buy)","published_at":"2021-01-08T22:06:48.000Z","date":"2021-01-06","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on January 6, 2021 and vests over one year in twelve equal monthly installments, commencing on February 6, 2021."}],"balance_after":10000,"derivative":{"exercise_price":66.49,"expiration_date":"2031-01-05","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001179110-21-000461","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000117911021000461/edgar.xml","form_type":"4"}},{"id":2912629,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-08T22:06:48.000Z","date":"2021-01-06","kind":"grant","acquired":true,"shares":1650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock units (\"RSUs\") granted on January 6, 2021 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 8, 2021 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 6, 2022."}],"balance_after":2613,"source":{"system":"sec-edgar","filing":"0001179110-21-000461","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000117911021000461/edgar.xml","form_type":"4"}},{"id":2950440,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-10T21:09:49.000Z","date":"2020-12-08","kind":"sale","acquired":false,"shares":687,"price":62.524,"value":42953.988,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $62.49 to $62.53 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":963,"source":{"system":"sec-edgar","filing":"0001179110-20-011806","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000117911020011806/edgar.xml","form_type":"4"}},{"id":3103147,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-22T20:19:21.000Z","date":"2020-06-19","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The entire number of shares subject to this option become fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":12500,"derivative":{"exercise_price":23.23,"expiration_date":"2020-06-18","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-20-038161","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919120038161/doc4.xml","form_type":"4"}},{"id":3104057,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-19T18:24:19.000Z","date":"2020-06-19","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest and become exercisable in full on the earlier of (i) June 19, 2021 or (ii) the day prior to the issuer's 2021 annual meeting of stockholders, subject to the director's continued service on the issuer's board of directors on the vesting date."}],"balance_after":8000,"derivative":{"exercise_price":27.89,"expiration_date":"2030-06-18","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001209191-20-038052","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919120038052/doc4.xml","form_type":"4"}},{"id":3296982,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right To Buy)","published_at":"2020-01-31T21:45:44.000Z","date":"2020-01-29","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on January 29, 2020 and vests over one year in twelve equal monthly installments, commencing on February 29, 2020."}],"balance_after":10000,"derivative":{"exercise_price":51.16,"expiration_date":"2030-01-28","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001070081-20-000055","document":"wf-form4_158050712715119.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000107008120000055/wf-form4_158050712715119.xml","form_type":"4"}},{"id":3296981,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-01-31T21:45:44.000Z","date":"2020-01-29","kind":"grant","acquired":true,"shares":1650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock units (\"RSUs\") granted on January 29, 2020 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 10, 2020 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 29, 2021."}],"balance_after":1650,"source":{"system":"sec-edgar","filing":"0001070081-20-000055","document":"wf-form4_158050712715119.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000107008120000055/wf-form4_158050712715119.xml","form_type":"4"}},{"id":3460791,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-07-16T23:56:19.000Z","date":"2019-07-15","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become exercisable in three substantially equal annual installments on each of the first three anniversaries of the grant date, subject to continued service as a director through each such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":24.15,"expiration_date":"2029-07-14","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-19-042286","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919119042286/doc4.xml","form_type":"4"}},{"id":3478570,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-25T16:56:09.000Z","date":"2019-06-21","kind":"grant","acquired":true,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest and become exercisable in full on the earlier of (i) June 21, 2020 or (ii) the day prior to the issuer's 2020 annual meeting of stockholders, subject to the director's continued service on the issuer's board of directors on the vesting date."}],"balance_after":5500,"derivative":{"exercise_price":31.22,"expiration_date":"2029-06-20","underlying":"Common Stock","underlying_shares":5500},"source":{"system":"sec-edgar","filing":"0001209191-19-038971","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919119038971/doc4.xml","form_type":"4"}},{"id":3688332,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-01-24T22:50:36.000Z","date":"2019-01-22","kind":"grant","acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on January 22, 2019 and vests over one year in twelve equal monthly installments, commencing on February 22, 2019."}],"balance_after":14000,"derivative":{"exercise_price":33.02,"expiration_date":"2029-01-21","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001104659-19-003203","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000110465919003203/a4.xml","form_type":"4"}},{"id":3727640,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right To Buy)","published_at":"2018-12-18T13:46:43.000Z","date":"2018-12-14","kind":"grant","acquired":true,"shares":1167,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1167,"derivative":{"exercise_price":33.63,"exercise_date":"2019-01-03","expiration_date":"2028-12-13","underlying":"Common Stock","underlying_shares":1167},"source":{"system":"sec-edgar","filing":"0001070081-18-000087","document":"wf-form4_154514078641248.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000107008118000087/wf-form4_154514078641248.xml","form_type":"4"}},{"id":3727639,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right To Buy)","published_at":"2018-12-18T13:46:43.000Z","date":"2018-12-14","kind":"grant","acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option award vests in thirty-six approximately equal monthly installments, commencing on January 14, 2019 and continuing on each successive monthly anniversary of thereafter, ending on the third year anniversary of the grant date."}],"balance_after":14000,"derivative":{"exercise_price":33.63,"expiration_date":"2028-12-13","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001070081-18-000087","document":"wf-form4_154514078641248.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000107008118000087/wf-form4_154514078641248.xml","form_type":"4"}},{"id":3890421,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-18T17:36:40.000Z","date":"2018-06-18","kind":"grant","acquired":true,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest and become exercisable in full on the earlier of (i) June 15, 2019 or (ii) the day prior to the issuer's 2019 annual meeting of stockholders, subject to the director's continued service on the issuer's board of directors on the vesting date."}],"balance_after":5500,"derivative":{"exercise_price":32.53,"expiration_date":"2028-06-14","underlying":"Common Stock","underlying_shares":5500},"source":{"system":"sec-edgar","filing":"0001209191-18-038380","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919118038380/doc4.xml","form_type":"4"}},{"id":3898102,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":17935,"kind":"person","name":"Okey Stephanie","position":1,"cik":"0001742616","reported_name":"Okey Stephanie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-11T16:19:56.000Z","date":"2018-06-08","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest and become exercisable in equal annual installments on the first three anniversaries of the date of grant (but, in any case, to be fully vested on the day prior to the annual meeting for the third fiscal year that begins following the date of grant)."}],"balance_after":11000,"derivative":{"exercise_price":30.68,"expiration_date":"2028-06-07","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001209191-18-036937","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919118036937/doc4.xml","form_type":"4"}}]}